-NYSE Group Markets Have 190 Primary ETF Listings-
New HealthSharesTM European Medical Products and Devices ETF Lists on NYSE Group
New York , June 1, 2007–NYSE Euronext subsidiary, NYSE Group, Inc. (NYSE Euronext: NYX) today announced that the HealthShares European Medical Products and Devices exchange-traded fund, began trading on the NYSE under the ticker symbol HHT. The 18th HealthShares™ product to list on the Exchange, the HealthShares European Medical Products and Devices ETF is based on an index comprised of European companies involved in all phases of the research, development and distribution of medical devices for the treatment of various human diseases and disorders.
“We are pleased to add another HealthShares ETF trading alongside the 17 HealthShares ETF already listed at the NYSE,” said NYSE Euronext Senior Vice President, Exchange Traded Funds and Indexes, Lisa Dallmer. “Today’s listing further solidifies our strong position in the popular ETF market and reiterates NYSE Euronext’s commitment to expanding our global footprint by offering investors the most diverse list of products coupled with our superior trading technology.”
Including today’s listings, NYSE Group markets have 190 primary ETF listings and trade all other eligible ETFs on a UTP basis. In first-quarter 2007, NYSE Group handled 45% of all ETF shares traded in the U.S. market. As the largest exchange group for ETF trading, NYSE Group is committed to offering investors the most innovative new investment options with superior pricing and market quality.
For more information and data on NYSE Group listed ETFs and other products, please visit: http://www.nyse.com/etfs.
XShares Advisors LLC, a financial services company based in New York , is the creator of the HealthShares™ family of Exchange Traded Funds (ETFs). HealthShares™ ETFs are organized into therapeutic ‘Verticals’ and represent specific areas of the healthcare, life science and biotechnology industries. Each Vertical addresses a distinct sub-segment of healthcare, such as the diagnosis and treatment of specific therapeutic areas (e.g. cardiology, cancer, infectious disease, etc.) and the development of medical devices (e.g. orthopedic repair, cardio devices, etc.). Each ETF tracks an index of 22-25 stocks and offers institutional and individual investors a more precise financial instrument that leverages the potential of healthcare investing while mitigating the risks of single stock picking.
About NYSE Euronext
NYSE Euronext, a holding company created by the combination of NYSE Group, Inc. and Euronext N.V., commenced trading on April 4, 2007 . NYSE Euronext (NYSE Euronext: NYX) operates the world’s largest and most liquid exchange group and offers the most diverse array of financial products and services. NYSE Euronext, which brings together six cash equities exchanges in five countries and six derivatives exchanges in six countries, is a world leader for listings, trading in cash equities, equity and interest rate derivatives, bonds and the distribution of market data. Representing a combined €21.7/$29.6 trillion total market capitalization of listed companies and average daily trading value of approximately €85/$115 billion (as of April 30, 2007), NYSE Euronext seeks to provide the highest standards of market quality and integrity, innovative products and services to investors, issuers, and all users of its markets.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning NYSE Euronext’s plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on NYSE Euronext’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause NYSE Euronext’s results to differ materially from current expectations include, but are not limited to: NYSE Euronext’s ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk and U.S. and global competition, and other factors detailed in NYSE Euronext Registration Statement (document de base) filed with the French Autorité des Marchés Financiers (Registered on November 30, 2006 under No. 06-0184), 2006 Annual Report on Form 10-K, as amended, and other periodic reports filed with the U.S. Securities and Exchange Commission or the French Autorité des Marchés Financiers. In addition, these statements are based on a number of assumptions that are subject to change. Accordingly, actual results may be materially higher or lower than those projected. The inclusion of such projections herein should not be regarded as a representation by NYSE Euronext that the projections will prove to be correct. This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.